SSTR2 (Somatostatin Receptor2) is widely expressed in solid tumors. Since it is highly expressed in neuroendocrine tumors (NETs), SSTR2 is the key target for the treatment of NETs at present.

Recent studies have shown that SSTR2 is significantly methylated in colorectal cancer and has also been implicated in tumorigenesis in gastric and breast cancers. Furthermore, the researchers found that SST binding to SSTR2 inhibited the release of cytokines from immune cells and impacted on the tumor microenvironment (TME).

SSTR2 is a member of the G protein-coupled receptor (GPCR) family and a seven-pass transmembrane protein with the N-terminal extracellular and the C-terminal intracellular. ACROBiosystems has successfully developed HEK293 expressed full-length SSTR2-VLP protein (Met 1-Ile 369) via "FLAG" to support drugs and therapies R&D targeting SSTR2.

◆Full-length SSTR2 6-VLP Protein (Cat. No. SS2-H5216)

High bioactivity verified by ELISA

Immobilized Human SSTR2 Full Length Protein-VLP (Cat. No. SS2-H5216) at 10 μg/mL (100 μL/well) can bind Anti SSTR2 Monoclonal Antibody, Mouse IgG with a linear range of 0.005-0.625 μg/mL (QC tested).